N/A
N=956
Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents
Human Papillomavirus
Bottom Line
View on ClinicalTrials.gov: NCT02236273 ↗Enrolled (actual)
956
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Number of Participants Who Completed HPV Vaccine Series — 364; 344 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Conventional text message reminder (Behavioral); Enhanced text message reminders (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Columbia University
- Primary completion
- Dec 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Completed HPV Vaccine Series |
364; 344 | — |
| SECONDARY Time Between 1st and 2nd Dose |
84.1; 82.8 | — |
| SECONDARY Time Between 1st and 3rd Dose |
210; 210 | — |
Summary
Emerging communication technologies, such as text messaging offer low-cost, scalable opportunities to improve health literacy and promote healthy behaviors, such as vaccination. While the investigators reported the success of text message vaccine reminders, effects were limited by their untailored approach. The trans-theoretical model of behavior change supports tailoring interventions to an individual's stage of decision-making. Human papillomavirus (HPV) is the most prevalent sexually transmitted virus in the U.S. and can lead to genital warts, and cervical, anal and penile cancer. The three-dose vaccine is 90-100% efficacious. Minorities are at greatest risk for such cancers but have low HPV vaccine completion rates. Limited health literacy regarding the vaccine can affect series completion. The investigators will compare the effects of enhancing text message vaccination reminders with interactive, vaccine health literacy-promoting information tailored to vaccine decision making-stage on HPV vaccine series completion. The effects of these messages represent a new paradigm in interactive health communications.
Eligibility Criteria
Inclusion Criteria
- Parenting adult of adolescent age 11-17 years
- Adolescent received 1st dose of HPV at a study site within the last 2 weeks.
- Eligible parent's cell phone has text message capability
Exclusion Criteria
- Language other than English or Spanish only
- Parent already in the study
- Intends to move away from the New York City area in <12 months
Data sourced from ClinicalTrials.gov (NCT02236273). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.